Marker Therapeutics MRKR
NASDAQ MRKR
$1.07 -0.06 (-5.31%)
At close: Oct 22, 2026 · 4:00 PM EDT

Marker Therapeutics (MRKR) Operating Interest Expenses (2013 - 2014)

Updated

Marker Therapeutics' Operating Interest Expenses came in at $35,269 for Q1 2014, down 89.5% from $334,888 a year earlier.

Analysis

Marker Therapeutics (MRKR) Operating Interest Expenses (2013 - 2014) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Interest Exp. (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn -
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn -
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn -
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn -
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn -
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn -
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn -
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn -
10 Marker Therapeutics 20.86 Mn -39.04 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2014 35,269.00
Mar 31, 2013 334,888.00
API Access

Marker Therapeutics Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-interest-expenses&ticker=MRKR&period=max&api_key=YOUR_API_KEY